Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion.
Wenjie ZiJiaxing SongWeilin KongJiacheng HuangChangwei GuoWencheng HeYinquan YuBo ZhangWanjie GengXiaolin TanYaoyu TianZongtao LiuMinghua CaoDaoyou ChengBo LiWenguo HuangJunsheng LiuPengfei WangZhou YuHao LiangShuang YangMingshan TangWenhua LiuXianjun HuangShugai LiuYufeng TangYoulin WuLi YaoZhu ShiPengcheng HeHaojin ZhaoZhuo ChenJun LuoYue WanQiang ShiMaorong WangDe YangXianglin ChenFang HuangJinlin MuHao LiZhimin LiJingbang ZhengShunli XieTieying CaiYuqi PengWeihua XieZhong Ming QiuChang LiuChengsong YueLinyu LiYan TianDahong YangJian MiaoJie YangJinrong HuRaul G NogueiraDuolao WangJeffrey L SaverFengli LiQing-Wu Yangnull nullPublished in: The New England journal of medicine (2023)
In this trial involving heterogeneous groups of patients with stroke of recent onset or progression of stroke symptoms and nonoccluded large and medium-sized cerebral vessels, intravenous tirofiban was associated with a greater likelihood of an excellent outcome than low-dose aspirin. Incidences of intracranial hemorrhages were low but slightly higher with tirofiban. (Funded by the National Natural Science Foundation of China; RESCUE BT2 Chinese Clinical Trial Registry number, ChiCTR2000029502.).
Keyphrases
- low dose
- atrial fibrillation
- clinical trial
- high dose
- cerebral ischemia
- study protocol
- phase ii
- public health
- phase iii
- randomized controlled trial
- cardiovascular disease
- subarachnoid hemorrhage
- type diabetes
- cardiovascular events
- antiplatelet therapy
- open label
- percutaneous coronary intervention
- acute coronary syndrome
- optic nerve